Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 26:11:1180.
doi: 10.3389/fimmu.2020.01180. eCollection 2020.

Modulation of Inflammation-Induced Tolerance in Cancer

Vladimir Rogovskii  1
Affiliations
Review

Modulation of Inflammation-Induced Tolerance in Cancer

Vladimir Rogovskii. Front Immunol. .
No abstract available

Keywords: anti-inflammatory therapy; cancer; immune suppression; immune tolerance; inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
It is reasonable to highlight the three types of inflammatory microenvironments: highly activated state, intermediate state, and the resolved state. Cancer is often associated with the intermediate state [para-inflammation (6)]. Most current therapeutic efforts are directed toward increasing inflammation toward the highly activated state. However, this is often associated with internal compensative mechanisms resulting in subsequent immune suppression (negative feedback). That may be the reason for the limited efficiency of ICIs, which dramatically increase inflammation at the whole-organism level (11). A better way may be to reduce inflammation with the aim of subsequent activation of the normal process of immune rejection of tumors (fast and without entering the cycle of chronic inflammation)—it might be called the immunological reload. Nevertheless, there still may be non-immune factors in the tumor microenvironment that decrease the immune response. For example, high levels of oxidized low-density lipoproteins and lactate (12). They also should be eliminated.
See this image and copyright information in PMC

References

    1. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. (2014) 2014:149185. 10.1155/2014/149185 - DOI - PMC - PubMed
    1. Rogovskii VS. The linkage between inflammation and immune tolerance: interfering with inflammation in cancer. Curr Cancer Drug Targets. (2017) 17:325–32. 10.2174/1568009617666170109110816 - DOI - PubMed
    1. Peter Medawar – Nobel Lecture NobelPrize.org: Nobel Media AB 2019. Available online at: https://www.nobelprize.org/prizes/medicine/1960/medawar/lecture/ (accessed November 20, 2019).
    1. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. (2018) 128:2657–69. 10.1172/JCI97943 - DOI - PMC - PubMed
    1. Medzhitov R. Origin and physiological roles of inflammation. Nature. (2008) 454:428–35. 10.1038/nature07201 - DOI - PubMed

LinkOut - more resources